Free Trial
→ $5,000 DOGE check? (From Altimetry) (Ad)

CEL-SCI 8/15/2024 Earnings Report

CEL-SCI logo
$0.40 -0.03 (-6.38%)
As of 02/21/2025 04:00 PM Eastern
Earnings History

CEL-SCI EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

CEL-SCI Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CEL-SCI Announcement Details

Quarter
Date
8/15/2024
Time
After Market Closes

Conference Call Resources

CEL-SCI Earnings Headlines

CEL-SCI to initiate Multikine cancer trial
February 20 at 11:40 PM | markets.businessinsider.com
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
February 20 at 8:00 AM | businesswire.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
CEL-SCI (NYSE:CVM) & BioAtla (NASDAQ:BCAB) Head to Head Comparison
February 20 at 2:55 AM | americanbankingnews.com
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
February 19 at 2:03 AM | finance.yahoo.com
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com
February 18, 2025 | americanbankingnews.com
See More CEL-SCI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CEL-SCI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CEL-SCI and other key companies, straight to your email.

About CEL-SCI

CEL-SCI (NYSE:CVM), a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

View CEL-SCI Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles